Diffusion Pharmaceuticals is a clinical stage biotechnology company focused on improving the results of cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple FDA Orphan-designated indications.
TSC modifies the tumor micro-environment, allowing enhanced therapeutic effects from radiation therapy and chemotherapy without the addition of harmful side effects.
Diffusion Pharmaceuticals is dedicated to extending the life expectancy of patients with treatment-resistant cancerous tumors, including GBM, pancreatic cancer and brain metastases.
Diffusion Pharmaceuticals is developing TSC for the improved treatment of life-threatening cancers in which tumor hypoxia (oxygen deprivation) diminishes the effectiveness of radiation therapy and chemotherapy.
Get the latests news first.
Subscribe to our newsletter.